OrbiMed’s Spyre Therapeutics SYRE Stock Holding History

OrbiMed’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.5M	Buy	+186,145	New	+$13.6M	0.31%	71
2023 Q2	–	Sell	-71,889	Closed	-$521K	–	136
2023 Q1	$521K	Hold	71,889	–	–	0.01%	120
2022 Q4	$809K	Hold	71,889	–	–	0.02%	113
2022 Q3	$945K	Hold	71,889	–	–	0.02%	129
2022 Q2	$908K	Sell	71,889 -46,356	-39%	-$1.62M	0.02%	141
2022 Q1	$6.8M	Hold	118,245	–	–	0.11%	111
2021 Q4	$14M	Sell	118,245 -42,376	-26%	-$6.69M	0.18%	102
2021 Q3	$31.9M	Hold	160,621	–	–	0.35%	74
2021 Q2	$27.9M	Hold	160,621	–	–	0.28%	84
2021 Q1	$31.8M	Hold	160,621	–	–	0.3%	80
2020 Q4	$31.6M	Hold	160,621	–	–	0.28%	80
2020 Q3	$28.5M	Hold	160,621	–	–	0.36%	72
2020 Q2	$37.1M	Buy	160,621 +46,000	+40%	+$8.76M	0.52%	55
2020 Q1	$13.4M	Hold	114,621	–	–	0.22%	80
2019 Q4	$21.9M	Hold	114,621	–	–	0.31%	63
2019 Q3	$22M	Buy	114,621 +28,000	+32%	+$5.45M	0.42%	56
2019 Q2	$14.8M	Hold	86,621	–	–	0.23%	80
2019 Q1	$17.4M	Hold	86,621	–	–	0.27%	79
2018 Q4	$16.2M	Hold	86,621	–	–	0.3%	75
2018 Q3	$20.7M	Buy	86,621 +12,000	+16%	+$2.8M	0.25%	88
2018 Q2	$19.7M	Buy	74,621 +15,840	+27%	+$3.9M	0.24%	93
2018 Q1	$14.6M	Hold	58,781	–	–	0.18%	92
2017 Q4	$7.95M	Hold	58,781	–	–	0.1%	109
2017 Q3	$7.24M	Hold	58,781	–	–	0.07%	114
2017 Q2	$5.66M	Hold	58,781	–	–	0.06%	111
2017 Q1	$10.9M	Buy	58,781 +4,372	+8%	+$617K	0.12%	92
2016 Q4	$5.92M	Hold	54,409	–	–	0.08%	109
2016 Q3	$8.72M	Hold	54,409	–	–	0.1%	104
2016 Q2	$6.61M	Buy	+54,409	New	+$10.4M	0.07%	107

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

OrbiMed's SYRE Position: Q2 2026 in Review

OrbiMed opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 186,145 shares worth $16.5M. The stake represents 0.31% of the portfolio and ranks #71 among its holdings. This is a return to the name: OrbiMed previously reported a position in SYRE as recently as Q1 2023.

OrbiMed first reported a position in SYRE in Q2 2016 and has held it in 29 quarters since. The position peaked at $37.1M in Q2 2020. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

OrbiMed held 186,145 shares of Spyre Therapeutics worth $16.5M as of Q2 2026.
Spyre Therapeutics was a new OrbiMed position in Q2 2026.
Spyre Therapeutics made up 0.31% of OrbiMed's portfolio in Q2 2026, its #71 holding.
OrbiMed first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 29 quarters since.
OrbiMed's Spyre Therapeutics position peaked at $37.1M in Q2 2020.
266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.